Learn more at LeadIQ.com

Insights

Expanding Product Line Kyverna Therapeutics is developing a diverse pipeline of cell therapies targeting autoimmune diseases, including innovative chimeric antigen receptor (CAR) T-cell therapies. This variety of treatment options presents an opportunity to cater to a wide range of autoimmune conditions and patient populations.

Recent Public Offering Kyverna Therapeutics recently went public, raising significant funding and garnering investor interest. This milestone indicates growth potential and a chance for strategic partnerships or collaborations that could drive sales expansion.

Experienced Leadership With the appointment of seasoned executives like Shaw, Biddle, and Aktar, Kyverna Therapeutics has bolstered its leadership team with a wealth of industry experience. Leveraging this leadership expertise can help in forging strong relationships, building credibility, and opening doors to new sales opportunities.

Market Recognition Kyverna's focus on developing cell therapies for autoimmune diseases has earned it a prominent position in the biotechnology industry, as evident from its successful IPO and strategic decision-making. This visibility could translate into increased customer trust, investor confidence, and potential collaborations that drive sales growth.

Financial Stability and Revenue Growth Despite being a relatively young company, Kyverna Therapeutics has shown steady revenue growth and secured substantial funding. This financial stability not only indicates operational strength but also can be leveraged to invest in sales and marketing strategies to capitalize on emerging market opportunities.

Similar companies to Kyverna Therapeutics

Kyverna Therapeutics Tech Stack

Kyverna Therapeutics uses 8 technology products and services including Google Analytics, WordPress, MySQL, and more. Explore Kyverna Therapeutics's tech stack below.

Google Analytics
Analytics
WordPress
Content Management System
MySQL
Database
ComplianceWire
Education Management
Divi
Page Builders
Microsoft Azure
Platform As A Service
Workable
Recruitment Marketing
Google Tag Manager
Tag Management

Media & News

Kyverna Therapeutics's Email Address Formats

Kyverna Therapeutics uses at least 1 format(s):

Kyverna Therapeutics Email Formats	Example	Percentage
FLast@kyvernatx.com	JDoe@kyvernatx.com	96%
Last@kyvernatx.com	Doe@kyvernatx.com	2%
FL@kyvernatx.com	JD@kyvernatx.com	1%
FMiddleLast@kyvernatx.com	JMichaelDoe@kyvernatx.com	1%

Frequently Asked Questions

Where is Kyverna Therapeutics's headquarters located?

Kyverna Therapeutics's main headquarters is located at 5980 Horton St Suite 550 Emeryville, California 94608 US. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is Kyverna Therapeutics's stock symbol?

Kyverna Therapeutics is a publicly traded company; the company's stock symbol is KYTX.

What is Kyverna Therapeutics's official website and social media links?

Kyverna Therapeutics's official website is kyvernatx.com and has social profiles on LinkedIn.

How much revenue does Kyverna Therapeutics generate?

As of September 2024, Kyverna Therapeutics's annual revenue reached $15M.

What is Kyverna Therapeutics's SIC code NAICS code?

Kyverna Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Kyverna Therapeutics have currently?

As of September 2024, Kyverna Therapeutics has approximately 127 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Technical Officer: K. W.Chief Medical Officer: J. C.Head Of Corporate Strategy And Investor Relations: G. T.. Explore Kyverna Therapeutics's employee directory with LeadIQ.

What industry does Kyverna Therapeutics belong to?

Kyverna Therapeutics operates in the Biotechnology Research industry.

What technology does Kyverna Therapeutics use?

Kyverna Therapeutics's tech stack includes Google AnalyticsWordPressMySQLComplianceWireDiviMicrosoft AzureWorkableGoogle Tag Manager.

What is Kyverna Therapeutics's email format?

Kyverna Therapeutics's email format typically follows the pattern of . Find more Kyverna Therapeutics email formats with LeadIQ.

How much funding has Kyverna Therapeutics raised to date?

As of September 2024, Kyverna Therapeutics has raised $60M in funding. The last funding round occurred on Aug 03, 2023 for $60M.

When was Kyverna Therapeutics founded?

Kyverna Therapeutics was founded in 2018.

Kyverna Therapeutics

Kyverna Therapeutics

Biotechnology ResearchCalifornia, United States51-200 Employees

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. 

Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Company Overview

Headquarters: 5980 Horton St Suite 550 Emeryville, California 94608 US
Website: kyvernatx.com
SIC Code: 8733 - Noncommercial Research Organizations
Stock Symbol: KYTX
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2018
Employees: 51-200

Media & News

Funding & Financials

$60M
Kyverna Therapeutics has raised a total of $60M of funding over 3 rounds. Their latest funding round was raised on Aug 03, 2023 in the amount of $60M.
$10M$50M
Kyverna Therapeutics's revenue is in the range of $10M$50M

Funding & Financials

$60M
Kyverna Therapeutics has raised a total of $60M of funding over 3 rounds. Their latest funding round was raised on Aug 03, 2023 in the amount of $60M.
$10M$50M
Kyverna Therapeutics's revenue is in the range of $10M$50M

Company Leadership

K. W.
Chief Technical Officer
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
J. C.
Chief Medical Officer
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
G. T.
Head Of Corporate Strategy And Investor Relations
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
D. B.
President, R&d
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
D. M.
Svp, Partnerships & Alliances
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Employee Directory

S. B.
Vice President, Program Lead
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
J. F.
Vp, Head Of Gxp Quality
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
P. S.
Vp Of Human Resources
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
T. V. B.
Senior Vice President, Head Of Research
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
P. W.
Vp, Head Of Clinical Development & Operations
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Kyverna Therapeutics and Millions of Other Companies
Sign up for full access to Kyverna Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Go to Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.